Ciloa SAS, a pioneering leader in the bioengineering of extracellular vesicles, has successfully raised $6,500,000 to accelerate its revolutionary vision for next-generation therapeutics and preventive healthcare solutions. For over 20 years, Ciloa has harnessed its unparalleled expertise to develop its breakthrough EVENGI platform, which transforms small extracellular vesicle (sEV) proteins into natural messengers with immense medical potential. With a keen focus on tackling some of the most challenging medical fields, from oncology and metabolic diseases to rare and age-related conditions, the company has refined a robust process for sEV production, purification, and qualification—capable of scaling under industrial conditions.
The recent funding injection will primarily support the expansion of Ciloa’s innovative research and development efforts, facilitating the advancement of their stable, multimerised, and functional adiponectin (APN)-loaded sEVs. Known as the “Guardian Angel” for its insulin-sensitizing, anti-inflammatory, and anti-oxidative stress properties, APN is a cornerstone in the therapeutic potential of these bioengineered vesicles. By investing in further optimization of the EVENGI platform, Ciloa aims to accelerate the pipeline of generating dozens of ready-to-use, affordable bioengineered sEVs that promise extended shelf-life and consistent performance as medicines.
This significant funding milestone not only reinforces the market’s confidence in Ciloa’s cutting-edge technology but also paves the way for expanded clinical applications. As the company continues to push the boundaries of bioengineering, the infusion of funds will empower Ciloa to bring innovative, high-impact therapies closer to patients in need across a diverse range of debilitating diseases.
